Welcome to our dedicated page for AbbVie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on AbbVie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie (ABBV) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, including a management fireside chat.
The discussion is scheduled for 9:00 a.m. Central time and will be available via live audio webcast on AbbVie’s Investor Relations website, with an archived replay accessible later that day.
AbbVie (ABBV), through its Allergan Aesthetics unit, released the global Layered Beauty: The New Aesthetic Mindset report, based on research among more than 12,000 beauty-involved consumers across nine markets. The report examines evolving attitudes toward beauty, aging and aesthetic treatments.
Findings highlight a shift from one-time procedures to personalized, long-term, multimodal treatment plans, growing focus on skin quality as the base of aesthetic care, and continued reliance on healthcare provider expertise. Regional differences in beauty ideals underscore the need for localized approaches. The full report is available at global.allerganaesthetics.com/layered-beauty.
AbbVie (NYSE: ABBV), via its Allergan Aesthetics unit, expanded the SkinMedica regenerative skincare line with the launch of Barrier Calming Cream, a restorative moisturizer aimed at soothing skin and supporting the skin barrier. Clinical testing showed a 30% reduction in skin dryness after two weeks. The cream uses a Calcium Strengthening Complex and Botanical Calming Complex to promote barrier resilience, calm visible redness, and improve hydration.
SkinMedica also introduced HA5 Hydra Collagen Facial Mist with vegan collagen and five forms of hyaluronic acid, which immediately increased skin hydration by 31% and improved dryness by 62% in testing. The cream ($140) and mist ($58) are available via SkinMedica.com and select medical providers. AbbVie notes SkinMedica products are cosmetics, not FDA-approved drugs.
AbbVie (NYSE: ABBV) will participate in the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. Company management will join a fireside chat at 9:15 a.m. Central time, with a live audio webcast and same-day archive available via AbbVie's investor relations website.
AbbVie (NYSE: ABBV) has submitted a regulatory application to the European Medicines Agency (EMA) for SKYRIZI (risankizumab) subcutaneous (SC) induction to treat adult patients with moderately to severely active Crohn's disease. The filing is supported by positive Phase 3 AFFIRM study data evaluating SC induction efficacy and safety.
SKYRIZI is already approved in the EU for intravenous (IV) induction and SC maintenance in Crohn's disease, as well as for plaque psoriasis, psoriatic arthritis and ulcerative colitis. If approved, Crohn's patients could choose either SC injection or IV infusion for induction, followed by SC maintenance every eight weeks.
AbbVie (NYSE: ABBV) will present extensive new data from its lung cancer portfolio at the 2026 World Conference on Lung Cancer, spanning NSCLC and SCLC.
Key highlights include Phase 1b results for ABBV-1480 (RC148) plus platinum chemotherapy in first-line advanced NSCLC, showing an objective response rate of 90.0% in squamous (27/30) and 75.9% in non-squamous (22/29) disease at the 10 mg/kg dose, which was selected as the recommended Phase 3 dose. Additional updates cover the telisotuzumab adizutecan (Temab-A) antibody-drug conjugate in first-line non-squamous and EGFR-mutated NSCLC, and ABBV-706 in relapsed/refractory SCLC, including new safety analyses from 240 patients and real-world data supporting SEZ6 as a potential target.
AbbVie (NYSE: ABBV) announced that 34 students living with inflammatory conditions will receive the 2026 AbbVie Immunology Scholarship, coinciding with the program’s 10th year. Since 2016, AbbVie has provided more than $6 million in scholarships, supporting over 350 U.S. students pursuing higher education.
According to AbbVie, the scholarship is now a renewable award of up to $20,000 per student, which recipients may renew for up to three additional years. The 2026 class includes 3 new recipients and 31 renewing their awards. The program supports students managing conditions such as atopic dermatitis, psoriasis, Crohn's disease, ulcerative colitis and juvenile idiopathic arthritis, and selection is based on academic achievement, leadership, community involvement, essays and recommendations.
Allergan Aesthetics (NYSE: ABBV) announced a refreshed Allergan Partner Privileges® (APP) loyalty program to better align with how modern aesthetics practices operate and grow. The update, shaped by customer feedback, focuses on simplified savings, clearer visibility into benefits, and expanded opportunities linked to portfolio-wide purchasing.
The revised APP structure streamlines Brand Tiers and pricing discounts, makes net pricing and APP status visible in real time, and introduces new Portfolio Levels that reward practice growth sooner. According to Allergan Aesthetics, new rewards are tailored for first-time APP members, growing practices, and long-standing loyal customers, plus an additional BOTOX® Cosmetic Growth Benefit offering eligible customers quarterly rebates tied to qualifying BOTOX® Cosmetic purchase growth.
Allergan Aesthetics (NYSE: ABBV), an AbbVie company, reported that the U.S. FDA has accepted for review a supplemental Biologics License Application for BOTOX® Cosmetic (onabotulinumtoxinA) to treat marked to very marked masseter muscle prominence (MMP) in adults.
If approved, BOTOX Cosmetic would become the first and only neurotoxin indicated for MMP in the U.S. and its fifth aesthetic indication. The sBLA is supported by two Phase 3 studies (M21-416 and M21-417), which met their primary endpoints, showing statistically significant improvements in masseter muscle prominence versus placebo (p=0.0046 and p=0.0014). Safety was consistent with established uses, with no new safety signals, and twice as many treated patients reported being “Very Satisfied” or “Satisfied” compared with placebo. The release also reiterates the existing boxed warning on distant spread of toxin effect, contraindications, key adverse reactions, and other important safety information for BOTOX Cosmetic.
AbbVie (NYSE:ABBV) reported second-quarter 2026 net revenues of $16.99 billion, up 10.2% reported (9.5% operational). GAAP diluted EPS rose 290.4% to $2.03, while adjusted diluted EPS increased 22.9% to $3.65, including a $0.17 per-share unfavorable impact from acquired IPR&D and milestones expense.
Immunology revenues were $8.786 billion (+15.1%), led by Skyrizi at $5.505 billion and Rinvoq at $2.525 billion, while Humira declined to $756 million. Neuroscience revenues reached $3.228 billion (+20.3%), oncology $1.650 billion (-1.5%), and aesthetics $1.282 billion (+0.3% reported, -0.9% operational).
AbbVie announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion in equity value, targeting IL‑13 and TSLP assets, with closing anticipated in third-quarter 2026. Full-year 2026 adjusted EPS guidance was updated from $13.91–$14.11 to $13.87–$14.07, now including an expected $0.14 per-share dilutive impact from the Apogee deal and an unfavorable $0.58 per-share impact from year-to-date acquired IPR&D and milestones expense.